Ultra-Short Acting Insulin Versus Short Acting Insulin Effect on Postprandial Hyperglycemia AKA RCT Comparing Viaject Versus Humalog in Pumps: Effect on Postprandial Glycemia.

Trial Profile

Ultra-Short Acting Insulin Versus Short Acting Insulin Effect on Postprandial Hyperglycemia AKA RCT Comparing Viaject Versus Humalog in Pumps: Effect on Postprandial Glycemia.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Insulin; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2017 Status changed from suspended to withdrawn prior to enrolment.
    • 01 Feb 2011 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
    • 19 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top